Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels

Pharmaceutical Research

Volumn 13, Issue 9, 1996, Pages 1313-1316

  Holladay, John W ^a   Dewey, Michael J ^a   Yoo, Sun D ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AAG; desipramine; imipramine; transgenic mice

Indexed keywords

DESIPRAMINE; DRUG METABOLITE; IMIPRAMINE; OROSOMUCOID;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BRAIN; DESIPRAMINE; FEMALE; IMIPRAMINE; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OROSOMUCOID; PROTEIN BINDING;

EID: 0029907071     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016005529420     Document Type: Article

References (18)

1. M. H. Bickel. Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components. J. Pharm. Pharmarol. 27:733-738 (1975).
2. C. B. Nemeroff, K. R. Krishinan, D. G. Blazer, D. L. Knight, D. Benjamin and L. R. Meyerson. Elevated plasma concentrations of alpha-1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site in depressed patients. Arch. Gen. Psychiatry 47 :337-340 (1990).
3. W. A. Kehoe, J. A. Kwentus, W. B. Sheffel and A. F. Harralson. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine. Biol. Psychiatry 29:489-493 (1991).
4. C. L. DeVane, J. W. Simpkins and S. A. Stout. Cerebral and blood pharmacokinetics of imipramine and its active metabolite in the pregnant rat. Psychopharmacology 84:225-230 (1984).
5. M. van Wijk and J. Korf. A quantitative study in the rat on the relationship between imipramine levels in brain and serum. Psychopharmacology. 76:48-51 (1982).
6. Y. Sato, S. Shibanoki, M. Sugahara and K. Ishikuwa. Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. Br. J. Pharmacol. 112:625-629 (1994).
7. C. L. DeVane and C. R. Jarecke. Cyclic antidepressants. In W. E. Evans, J. J. Sehentag and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics, Vancouver, 1992, pp. 33-1-33-47.
8. D. J. Greenblatt, E. M. Sellers and J. Koch-Weser. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol. 22:259-263 (1982).
9. P. Riant, S. Urien, E. Albengres A. Renouard and J. P. Tillement. Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain-barrier. J. Newrochem. 51:421-425 (1988).
10. S. D. Yoo, J. W. Holladay, T. K. Fincher, H. Baumann and M. J. Dewey. Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther. 276:918-922 (1996).
11. M. J. Dewey, C. Rheaume, F. G. Berger and H. Baumann. Inducible and tissue-specific expression of rat alpha-1-acid glycoprotein in transgenic mice. J. Immunol. 144:4392-4398 (1990).
12. S. A. Stout and C. L. DeVane. Quantification of imipramine and its major metabolites in whole blood, brain and other tissues of the rat by liquid chromatography. Psychopharmacology 84:39-41 (1984).
13. S. D. Yoo, J. W. Holladay, T. K. Fincher and M. J. Dewey. Rapid microsample analysis of imipramine and desipramine by reversed-phase high performance liquid chromatography with ultraviolet detection. J. Chromatogr. 668:1338-342 (1995).
14. W. D. Wessinger. Chronic administration of pencyclidine: pharmacokinetic comparison of intravenous and subcutaneous infusions in Sprague-Dawley rats. Drug Metab. Dispos. 19:719-721 (1991).
15. 3H]desipramine binding sites in the rat brain after acute and chronic treatment with imipramine. J. Pharm. Pharmacol. 43:31-35 (1991).
16. M. Qin. M. Nilsson and S Øie. Decreased elimination of drug in the presence of alpha-1-acid glycoprotein is related to a reduced hepatocyte uptake. J. Pharmacol. Exp. Ther. 269:1176-1181 (1994).
17. K. Brøsen and L. F. Gram. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 43:400-406 (1988).
18. S. Sindrup, K. Brøsen and L. F. Gram. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther. Drug Monit. 12:445-449 (1990).